Australia Earnings Roundup: CSL, Acrux, Pharmaxis, Mesoblast (Part 1)
This article was originally published in PharmAsia News
Executive Summary
PharmAsia News combs through earnings reports to bring you highlights on Australian biotech firms. We start with CSL Ltd, Acrux, Pharmaxis and Mesoblast for the period ended Dec. 31, 2012.
You may also be interested in...
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.
CSL CEO Brian McNamee On Being Australia’s Only Homegrown MNC: An Interview With PharmAsia News (Part 1 of 2)
Australia's only homegrown multinational company in the pharmaceutical sector, CSL is at the forefront of producing a novel A H1N1 influenza vaccine, having signed a $180 million contract with U.S. Dept of Health and Human Services to provide the vaccine antigen in bulk form. CSL is also the originator of Merck's HPV vaccine Gardasil. CEO Brian McNamee talked with PharmAsia News' Australia bureau about CSL's operations at home and abroad.
Cynata Sets Stage For Global Fujifilm Cell Therapy Deal
Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.